 | |
| Clinical data | |
|---|---|
| Trade names | Elanone-V |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.042.166 |
| Chemical and physical data | |
| Formula | C22H23F2NO2 |
| Molar mass | 371.428 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lenperone (Elanone-V) is atypical antipsychotic of thebutyrophenonechemical class.[1] It was first reported as ananti-emetic in 1974,[2] and its use in treatment of acuteschizophrenia was reported in 1975.[1] Related early antipsychotic agents includedeclenperone andmilenperone.
Lenperone was never approved by the FDA for use in humans in the United States,[3] but prior to 1989 it was approved for use in veterinary medicine for sedation.[4][5][6]
A synthesis of lenperone has been reported.[7][2][8][9] The alkylation between 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane (1) and 4-(4-fluorobenzoyl)piperidine (2) gives 2-(p-fluorophenyl)-2-{3-[4-(p-fluorobenzoyl)piperidino]propyl}-1,3-dioxolane,[10] (3). Deprotection of the ketal function completes the synthesis of lenperone (4).
Chemically related drugs containing the same 4-(p-fluorobenzoyl)piperidine group:
Table 1. Marketed butyrophenones with approval status and indication
The firm requested withdrawal of approval because the products are no longer being marketed. Effective date: July 13, 1989
